<DOC>
	<DOCNO>NCT02012049</DOCNO>
	<brief_summary>The purpose study conduct bioequivalence ( biological equivalence two preparation drug ) test healthy adult `` Risperdal OD Tab . 2mg '' Janssen Korea investigational drug `` Risperdal Quicklet Tab . 2mg '' control drug .</brief_summary>
	<brief_title>Bioequivalence Test Risperdal 2mg Janssen Korea</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) open label ( people know identity intervention ) study . All participant hospitalize research room subsequently restrict exercise , eating , drinking , smoke xanthine-beverages end blood collection . Water allow take one hour drug administration . Participants randomly assign two group , one group receive Risperdal OD ( investigational drug ) , one group receive Risperdal Quicklet ( control drug ) . On day test , blood collect participant provide baseline measurement . Subsequently , study drug orally administer participant , follow blood collection total 13 time point , 24 hour . After blood collection finish , participant discharge receive proper guidance examine psychologist . Following wash-out period ( period receive intervention ) one week , participant hospitalize crossed receive study drug follow procedure describe . The approximate study duration ( include drug administration day wash-out period ) approximately 10 day .</detailed_description>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Healthy Korean participant weigh 50kg within 20 % normal lean body weight ( standard weight ) Participant without congenital chronic disease symptoms finding result internal examination Participant deem appropriate result inquiry , blood pressure , physical examination , electrocardiogram , blood urinalysis , etc. , within 28 day prior first administration investigational drug accord protocol Female participant confirm nonpregnant urine test health examination Participant history disease related cardiac , respiratory , hepatic , renal , gastrointestinal nervous system , cardiac infarction , stroke , hypertension , arrhythmia , coronary artery disease , neuropsychiatric disease could affect drug absorption , distribution , metabolism excretion could risk factor take drug use clinical trial , history gastrointestinal surgery except appendectomy herniotomy , currently abnormality inquiry physical examination Participant show symptom suspect acute disease within 14 day first administration investigational drug Participant allergic disease require treatment Participant history hypersensitive drug food Patient hepatitis B antigen show hepatitis C positive antigen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Risperdal OD</keyword>
	<keyword>Risperdal Quicklet</keyword>
	<keyword>Korea</keyword>
</DOC>